Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01066104 · ClinicalTrials.gov registry record · Phase 2
Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01066104: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01066104 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01066104, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The investigators are doing this research study to learn more about a drug called Xolair (omalizumab). The investigators want to see if it is an effective treatment for chronic rhinosinusitis (CRS). Specifically, the investigators want to see whether Xolair will make nasal polyps smaller and less thick, and relieve symptoms in people with CRS. Polyps are abnormal growths of tissue that can grow in the lining of your sinuses (the inside of your nose). The investigators also want to find out if it is safe to use (whether it causes side effects).
Interventions
- DRUG Xolair placebo
- DRUG Xolair (omalizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-12 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01066104
The ClinicalTrials.gov registry entry for NCT01066104 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Xolair placebo is the first listed.
NCT01066104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01066104 about?
NCT01066104 is a clinical study titled "Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis". The investigators are doing this research study to learn more about a drug called Xolair (omalizumab). The investigators want to see if it is an effective treatment for chronic rhinosinusitis (CRS). Specifically, the investigators want to see whether Xolair will make nasal polyps smaller and less th...
What is the current status of trial NCT01066104?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2009-12. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01066104?
The interventions under investigation include: Xolair placebo (DRUG), Xolair (omalizumab) (DRUG).
Who is sponsoring clinical trial NCT01066104?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.